SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?


To: Scott H. Davis who wrote (459)1/6/1998 12:51:00 AM
From: James Yegerlehner  Respond to of 1972
 
All-

The news below refers to Genzyme's "proprietary lipid gene delivery systems.." This sure sounds similar to Vical's technology. Does anyone know anything about this technology infringing on Vical's patent, or the other way round?

biz.yahoo.com

>>
...SGP and the Genzyme Molecular Oncology unit of Genzyme Corp. (Nasdaq:GENZ - news) announced a research and option agreement to combine Genzyme Molecular Oncology's proprietary lipid gene delivery systems with several of SGP's proprietary genes, including the p53 tumor suppressor gene, to develop gene therapy products.
<<



To: Scott H. Davis who wrote (459)1/6/1998 10:34:00 PM
From: William Strop  Read Replies (2) | Respond to of 1972
 
Scott,

Your position that this risk averse market will stay away from what is not easily understood is probably the correct one in these times. What do you look at to see if the market sentiment has changed??? I still think you should own a few hundred & whine or wine with the rest of us!!!!

Bill